SPY325.60-4.38 -1.33%
DIA263.47-3.12 -1.17%
IXIC10,939.04-246.55 -2.20%

Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction With Immatics

NEW YORK, NY & HOUSTON, TX & TUEBINGEN, Germany--(BUSINESS WIRE)-- Arya Sciences Acquisition Corp. (NASDAQ:ARYA, Arya&rdquo, )), a special purpose acquisition company sponsored by Perceptive Advisors, and

Benzinga · 06/29/2020 20:16

NEW YORK, NY & HOUSTON, TX & TUEBINGEN, Germany--(BUSINESS WIRE)-- Arya Sciences Acquisition Corp. (NASDAQ:ARYA, Arya&rdquo, ))), a special purpose acquisition company sponsored by Perceptive Advisors, and Immatics Biotechnologies GmbH (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced that its respective shareholders approved the business combination between Arya and Immatics announced on March 17, 2020. None of Arya’s shareholders redeemed their shares in connection with the ARYA shareholder approval. The respective boards of directors of both Arya and Immatics had previously approved the business combination.

Following the Arya shareholder vote, Immatics and Arya commenced final procedures towards the closing of the business combination and expect the closing to be completed in the coming days. It is further expected that the trading of the shares of the combined company, called Immatics N.V., will commence under the symbol “IMTX” on the first trading day thereafter. Immatics will continue to operate under its existing management team led by Chief Executive Officer, Harpreet Singh, Ph.D.

About the Transaction
On March 17, 2020, Immatics entered into a definite business combination agreement with Arya and in connection with the entry into the business combination agreement, a group of leading U.S. healthcare institutional investors committed to invest in Immatics N.V. through an ordinary share private investment in public equity (“PIPE”). Immatics shareholders, Arya shareholders and the PIPE investors will hold shares in Immatics N.V.